Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

1(20%)

Results Posted

0%(0 trials)

Terminated

1(20%)

Phase Distribution

Ph early_phase_1

20%

Ph phase_1

20%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Early Phase 1First-in-human

1(25.0%)

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Terminated(1)

Other(1)

Detailed Status

Completed2

Recruiting1

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (25.0%)

Phase 11 (25.0%)

Phase 22 (50.0%)

Trials by Status

recruiting120%

terminated120%

unknown120%

completed240%

Recent Activity

1 active trials

Showing 5 of 5

recruitingearly_phase_1

Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection

NCT04361903

completedphase_2

Ruxolitinib for Steroid-refractory GVHD

NCT02997280

Clinical Trials (5)

Showing 5 of 5 trials

NCT06008275Early Phase 1

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Recruiting

NCT03701698Phase 2

Ruxolitinib and Steroid As First Line Therapy for Acute GVHD

Terminated

NCT04334044Phase 1

Treatment of SARS Caused by COVID-19 With Ruxolitinib

Completed

NCT04361903

Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection

Unknown

NCT02997280Phase 2

Ruxolitinib for Steroid-refractory GVHD

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5